APO Research
Talk to an analyst

APO RESEARCH · REPORT

T Cell Specific Surface Glycoprotein CD28

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global T Cell Specific Surface Glycoprotein CD28 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025182 pages

Choose your research edition.

Industry ResearchT Cell Specific Surface Glycoprotein CD28 Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal T Cell Specific Surface Glycoprotein CD28 Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal T Cell Specific Surface Glycoprotein CD28 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal T Cell Specific Surface Glycoprotein CD28 Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal T Cell Specific Surface Glycoprotein CD28 Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global T Cell Specific Surface Glycoprotein CD28 market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for T Cell Specific Surface Glycoprotein CD28 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for T Cell Specific Surface Glycoprotein CD28 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for T Cell Specific Surface Glycoprotein CD28 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for T Cell Specific Surface Glycoprotein CD28 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of T Cell Specific Surface Glycoprotein CD28 include Johnson & Johnson, TheraMAB LLC, Five Prime Therapeutics Inc, Bristol-Myers Squibb Co and Atox Bio Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global T Cell Specific Surface Glycoprotein CD28 market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of T Cell Specific Surface Glycoprotein CD28 and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents T Cell Specific Surface Glycoprotein CD28 sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the T Cell Specific Surface Glycoprotein CD28 market size, projected growth trends, production technologies, key applications, and end-use industries.

T Cell Specific Surface Glycoprotein CD28 Segment by Company

Johnson & Johnson

TheraMAB LLC

Five Prime Therapeutics Inc

Bristol-Myers Squibb Co

Atox Bio Ltd

T Cell Specific Surface Glycoprotein CD28 Segment by Type

Lulizumab Pegol

FR-104

FPT-155

Others

T Cell Specific Surface Glycoprotein CD28 Segment by Application

Plaque Psoriasis

Acute Renal Failure(ARF)

Solid Tumor

Others

T Cell Specific Surface Glycoprotein CD28 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global T Cell Specific Surface Glycoprotein CD28 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of T Cell Specific Surface Glycoprotein CD28 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of T Cell Specific Surface Glycoprotein CD28.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the T Cell Specific Surface Glycoprotein CD28 market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of T Cell Specific Surface Glycoprotein CD28 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of T Cell Specific Surface Glycoprotein CD28 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of T Cell Specific Surface Glycoprotein CD28 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. T Cell Specific Surface Glycoprotein CD28 Industry Trends Table 2. T Cell Specific Surface Glycoprotein CD28 Industry Drivers Table 3. T Cell Specific Surface Glycoprotein CD28 Industry Opportunities and Challenges Table 4. T Cell Specific Surface Glycoprotein CD28 Industry Restraints Table 5. Global T Cell Specific Surface Glycoprotein CD28 Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global T Cell Specific Surface Glycoprotein CD28 Revenue Market Share by Manufacturers (2021-2026) Table 7. Global T Cell Specific Surface Glycoprotein CD28 Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global T Cell Specific Surface Glycoprotein CD28 Sales Market Share by Manufacturers Table 9. Global T Cell Specific Surface Glycoprotein CD28 Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global T Cell Specific Surface Glycoprotein CD28 Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global T Cell Specific Surface Glycoprotein CD28 Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global T Cell Specific Surface Glycoprotein CD28 Manufacturers, Product Type & Application Table 13. Global T Cell Specific Surface Glycoprotein CD28 Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global T Cell Specific Surface Glycoprotein CD28 by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Lulizumab Pegol Table 17. Major Manufacturers of FR-104 Table 18. Major Manufacturers of FPT-155 Table 19. Major Manufacturers of Others Table 20. Global T Cell Specific Surface Glycoprotein CD28 Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global T Cell Specific Surface Glycoprotein CD28 Sales by Type (2021-2026) & (K Units) Table 22. Global T Cell Specific Surface Glycoprotein CD28 Sales by Type (2027-2032) & (K Units) Table 23. Global T Cell Specific Surface Glycoprotein CD28 Sales Market Share by Type (2021-2026) Table 24. Global T Cell Specific Surface Glycoprotein CD28 Sales Market Share by Type (2027-2032) Table 25. Global T Cell Specific Surface Glycoprotein CD28 Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global T Cell Specific Surface Glycoprotein CD28 Revenue by Type (2021-2026) & (K Units) Table 27. Global T Cell Specific Surface Glycoprotein CD28 Revenue by Type (2027-2032) & (K Units) Table 28. Global T Cell Specific Surface Glycoprotein CD28 Revenue Market Share by Type (2021-2026) Table 29. Global T Cell Specific Surface Glycoprotein CD28 Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Plaque Psoriasis Table 31. Major Manufacturers of Acute Renal Failure(ARF) Table 32. Major Manufacturers of Solid Tumor Table 33. Major Manufacturers of Others Table 34. Global T Cell Specific Surface Glycoprotein CD28 Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global T Cell Specific Surface Glycoprotein CD28 Sales by Application (2021-2026) & (K Units) Table 36. Global T Cell Specific Surface Glycoprotein CD28 Sales by Application (2027-2032) & (K Units) Table 37. Global T Cell Specific Surface Glycoprotein CD28 Sales Market Share by Application (2021-2026) Table 38. Global T Cell Specific Surface Glycoprotein CD28 Sales Market Share by Application (2027-2032) Table 39. Global T Cell Specific Surface Glycoprotein CD28 Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global T Cell Specific Surface Glycoprotein CD28 Revenue by Application (2021-2026) & (K Units) Table 41. Global T Cell Specific Surface Glycoprotein CD28 Revenue by Application (2027-2032) & (K Units) Table 42. Global T Cell Specific Surface Glycoprotein CD28 Revenue Market Share by Application (2021-2026) Table 43. Global T Cell Specific Surface Glycoprotein CD28 Revenue Market Share by Application (2027-2032) Table 44. Global T Cell Specific Surface Glycoprotein CD28 Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global T Cell Specific Surface Glycoprotein CD28 Sales by Region (2021-2026) & (K Units) Table 46. Global T Cell Specific Surface Glycoprotein CD28 Sales Market Share by Region (2021-2026) Table 47. Global T Cell Specific Surface Glycoprotein CD28 Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global T Cell Specific Surface Glycoprotein CD28 Sales Forecasted Market Share by Region (2027-2032) Table 49. North America T Cell Specific Surface Glycoprotein CD28 Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America T Cell Specific Surface Glycoprotein CD28 Sales by Country (2021-2026) & (K Units) Table 51. North America T Cell Specific Surface Glycoprotein CD28 Sales by Country (2027-2032) & (K Units) Table 52. Europe T Cell Specific Surface Glycoprotein CD28 Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe T Cell Specific Surface Glycoprotein CD28 Sales by Country (2021-2026) & (K Units) Table 54. Europe T Cell Specific Surface Glycoprotein CD28 Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific T Cell Specific Surface Glycoprotein CD28 Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific T Cell Specific Surface Glycoprotein CD28 Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific T Cell Specific Surface Glycoprotein CD28 Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa T Cell Specific Surface Glycoprotein CD28 Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa T Cell Specific Surface Glycoprotein CD28 Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa T Cell Specific Surface Glycoprotein CD28 Sales by Country (2027-2032) & (K Units) Table 61. Global T Cell Specific Surface Glycoprotein CD28 Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global T Cell Specific Surface Glycoprotein CD28 Revenue by Region (2021-2026) & (US$ Million) Table 63. Global T Cell Specific Surface Glycoprotein CD28 Revenue by Region (2027-2032) & (US$ Million) Table 64. Global T Cell Specific Surface Glycoprotein CD28 Revenue Market Share by Region (2021-2026) Table 65. Global T Cell Specific Surface Glycoprotein CD28 Revenue Market Share by Region (2027-2032) Table 66. Johnson & Johnson Company Information Table 67. Johnson & Johnson Business Overview Table 68. Johnson & Johnson T Cell Specific Surface Glycoprotein CD28 Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Johnson & Johnson T Cell Specific Surface Glycoprotein CD28 Product Portfolio Table 70. Johnson & Johnson Recent Development Table 71. TheraMAB LLC Company Information Table 72. TheraMAB LLC Business Overview Table 73. TheraMAB LLC T Cell Specific Surface Glycoprotein CD28 Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. TheraMAB LLC T Cell Specific Surface Glycoprotein CD28 Product Portfolio Table 75. TheraMAB LLC Recent Development Table 76. Five Prime Therapeutics Inc Company Information Table 77. Five Prime Therapeutics Inc Business Overview Table 78. Five Prime Therapeutics Inc T Cell Specific Surface Glycoprotein CD28 Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Five Prime Therapeutics Inc T Cell Specific Surface Glycoprotein CD28 Product Portfolio Table 80. Five Prime Therapeutics Inc Recent Development Table 81. Bristol-Myers Squibb Co Company Information Table 82. Bristol-Myers Squibb Co Business Overview Table 83. Bristol-Myers Squibb Co T Cell Specific Surface Glycoprotein CD28 Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Bristol-Myers Squibb Co T Cell Specific Surface Glycoprotein CD28 Product Portfolio Table 85. Bristol-Myers Squibb Co Recent Development Table 86. Atox Bio Ltd Company Information Table 87. Atox Bio Ltd Business Overview Table 88. Atox Bio Ltd T Cell Specific Surface Glycoprotein CD28 Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Atox Bio Ltd T Cell Specific Surface Glycoprotein CD28 Product Portfolio Table 90. Atox Bio Ltd Recent Development Table 91. Key Raw Materials Table 92. Raw Materials Key Suppliers Table 93. T Cell Specific Surface Glycoprotein CD28 Distributors List Table 94. T Cell Specific Surface Glycoprotein CD28 Customers List Table 95. Research Programs/Design for This Report Table 96. Authors List of This Report Table 97. Secondary Sources Table 98. Primary Sources List of Figures Figure 1. T Cell Specific Surface Glycoprotein CD28 Product Image Figure 2. Global T Cell Specific Surface Glycoprotein CD28 Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global T Cell Specific Surface Glycoprotein CD28 Market Size (2021-2032) & (US$ Million) Figure 4. Global T Cell Specific Surface Glycoprotein CD28 Sales (2021-2032) & (K Units) Figure 5. Global T Cell Specific Surface Glycoprotein CD28 Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 T Cell Specific Surface Glycoprotein CD28 Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Lulizumab Pegol Image Figure 9. FR-104 Image Figure 10. FPT-155 Image Figure 11. Others Image Figure 12. Global T Cell Specific Surface Glycoprotein CD28 Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global T Cell Specific Surface Glycoprotein CD28 Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global T Cell Specific Surface Glycoprotein CD28 Sales Market Share by Type (2021-2032) Figure 15. Global T Cell Specific Surface Glycoprotein CD28 Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global T Cell Specific Surface Glycoprotein CD28 Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global T Cell Specific Surface Glycoprotein CD28 Revenue Market Share by Type (2021-2032) Figure 18. Plaque Psoriasis Image Figure 19. Acute Renal Failure(ARF) Image Figure 20. Solid Tumor Image Figure 21. Others Image Figure 22. Global T Cell Specific Surface Glycoprotein CD28 Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global T Cell Specific Surface Glycoprotein CD28 Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global T Cell Specific Surface Glycoprotein CD28 Sales Market Share by Application (2021-2032) Figure 25. Global T Cell Specific Surface Glycoprotein CD28 Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global T Cell Specific Surface Glycoprotein CD28 Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global T Cell Specific Surface Glycoprotein CD28 Revenue Market Share by Application (2021-2032) Figure 28. North America T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America T Cell Specific Surface Glycoprotein CD28 Sales Market Share by Country (2021-2032) Figure 30. U.S. T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe T Cell Specific Surface Glycoprotein CD28 Sales Market Share by Country (2021-2032) Figure 35. Germany T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific T Cell Specific Surface Glycoprotein CD28 Sales Market Share by Country (2021-2032) Figure 42. China T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa T Cell Specific Surface Glycoprotein CD28 Sales Market Share by Country (2021-2032) Figure 50. Brazil T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile T Cell Specific Surface Glycoprotein CD28 Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global T Cell Specific Surface Glycoprotein CD28 Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global T Cell Specific Surface Glycoprotein CD28 Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America T Cell Specific Surface Glycoprotein CD28 Revenue (2021-2032) & (US$ Million) Figure 61. North America T Cell Specific Surface Glycoprotein CD28 Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe T Cell Specific Surface Glycoprotein CD28 Revenue (2021-2032) & (US$ Million) Figure 63. Europe T Cell Specific Surface Glycoprotein CD28 Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific T Cell Specific Surface Glycoprotein CD28 Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific T Cell Specific Surface Glycoprotein CD28 Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa T Cell Specific Surface Glycoprotein CD28 Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa T Cell Specific Surface Glycoprotein CD28 Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. T Cell Specific Surface Glycoprotein CD28 Value Chain Figure 69. Manufacturing Cost Structure Figure 70. T Cell Specific Surface Glycoprotein CD28 Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Lulizumab Pegol
  • FR-104
  • FPT-155
  • Others
Applications
  • Plaque Psoriasis
  • Acute Renal Failure(ARF)
  • Solid Tumor
  • Others
Companies covered
  • Johnson & Johnson
  • TheraMAB LLC
  • Five Prime Therapeutics Inc
  • Bristol-Myers Squibb Co
  • Atox Bio Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global T Cell Specific Surface Glycoprotein CD28 Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global T Cell Specific Surface Glycoprotein CD28 Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global T Cell Specific Surface Glycoprotein CD28 Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global T Cell Specific Surface Glycoprotein CD28 Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global T Cell Specific Surface Glycoprotein CD28 Market Dynamics
  1. 2.1 T Cell Specific Surface Glycoprotein CD28 Industry Trends
  2. 2.2 T Cell Specific Surface Glycoprotein CD28 Industry Drivers
  3. 2.3 T Cell Specific Surface Glycoprotein CD28 Industry Opportunities and Challenges
  4. 2.4 T Cell Specific Surface Glycoprotein CD28 Industry Restraints
3 T Cell Specific Surface Glycoprotein CD28 Market by Manufacturers
  1. 3.1 Global T Cell Specific Surface Glycoprotein CD28 Revenue by Manufacturers (2021-2026)
  2. 3.2 Global T Cell Specific Surface Glycoprotein CD28 Sales by Manufacturers (2021-2026)
  3. 3.3 Global T Cell Specific Surface Glycoprotein CD28 Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global T Cell Specific Surface Glycoprotein CD28 Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global T Cell Specific Surface Glycoprotein CD28 Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global T Cell Specific Surface Glycoprotein CD28 Manufacturers, Product Type & Application
  7. 3.7 Global T Cell Specific Surface Glycoprotein CD28 Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global T Cell Specific Surface Glycoprotein CD28 Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 T Cell Specific Surface Glycoprotein CD28 Players Market Share by Revenue in 2025
  11. 3.8.3 2025 T Cell Specific Surface Glycoprotein CD28 Tier 1, Tier 2, and Tier 3
4 T Cell Specific Surface Glycoprotein CD28 Market by Type
  1. 4.1 T Cell Specific Surface Glycoprotein CD28 Type Introduction
  2. 4.1.1 Lulizumab Pegol
  3. 4.1.2 FR-104
  4. 4.1.3 FPT-155
  5. 4.1.4 Others
  6. 4.2 Global T Cell Specific Surface Glycoprotein CD28 Sales by Type
  7. 4.2.1 Global T Cell Specific Surface Glycoprotein CD28 Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global T Cell Specific Surface Glycoprotein CD28 Sales by Type (2021-2032)
  9. 4.2.3 Global T Cell Specific Surface Glycoprotein CD28 Sales Market Share by Type (2021-2032)
  10. 4.3 Global T Cell Specific Surface Glycoprotein CD28 Revenue by Type
  11. 4.3.1 Global T Cell Specific Surface Glycoprotein CD28 Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global T Cell Specific Surface Glycoprotein CD28 Revenue by Type (2021-2032)
  13. 4.3.3 Global T Cell Specific Surface Glycoprotein CD28 Revenue Market Share by Type (2021-2032)
5 T Cell Specific Surface Glycoprotein CD28 Market by Application
  1. 5.1 T Cell Specific Surface Glycoprotein CD28 Application Introduction
  2. 5.1.1 Plaque Psoriasis
  3. 5.1.2 Acute Renal Failure(ARF)
  4. 5.1.3 Solid Tumor
  5. 5.1.4 Others
  6. 5.2 Global T Cell Specific Surface Glycoprotein CD28 Sales by Application
  7. 5.2.1 Global T Cell Specific Surface Glycoprotein CD28 Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global T Cell Specific Surface Glycoprotein CD28 Sales by Application (2021-2032)
  9. 5.2.3 Global T Cell Specific Surface Glycoprotein CD28 Sales Market Share by Application (2021-2032)
  10. 5.3 Global T Cell Specific Surface Glycoprotein CD28 Revenue by Application
  11. 5.3.1 Global T Cell Specific Surface Glycoprotein CD28 Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global T Cell Specific Surface Glycoprotein CD28 Revenue by Application (2021-2032)
  13. 5.3.3 Global T Cell Specific Surface Glycoprotein CD28 Revenue Market Share by Application (2021-2032)
6 Global T Cell Specific Surface Glycoprotein CD28 Sales by Region
  1. 6.1 Global T Cell Specific Surface Glycoprotein CD28 Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global T Cell Specific Surface Glycoprotein CD28 Sales by Region (2021-2032)
  3. 6.2.1 Global T Cell Specific Surface Glycoprotein CD28 Sales by Region (2021-2026)
  4. 6.2.2 Global T Cell Specific Surface Glycoprotein CD28 Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America T Cell Specific Surface Glycoprotein CD28 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America T Cell Specific Surface Glycoprotein CD28 Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe T Cell Specific Surface Glycoprotein CD28 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe T Cell Specific Surface Glycoprotein CD28 Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific T Cell Specific Surface Glycoprotein CD28 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific T Cell Specific Surface Glycoprotein CD28 Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa T Cell Specific Surface Glycoprotein CD28 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa T Cell Specific Surface Glycoprotein CD28 Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global T Cell Specific Surface Glycoprotein CD28 Revenue by Region
  1. 7.1 Global T Cell Specific Surface Glycoprotein CD28 Revenue by Region
  2. 7.1.1 Global T Cell Specific Surface Glycoprotein CD28 Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global T Cell Specific Surface Glycoprotein CD28 Revenue by Region (2021-2026)
  4. 7.1.3 Global T Cell Specific Surface Glycoprotein CD28 Revenue by Region (2027-2032)
  5. 7.1.4 Global T Cell Specific Surface Glycoprotein CD28 Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America T Cell Specific Surface Glycoprotein CD28 Revenue (2021-2032)
  8. 7.2.2 North America T Cell Specific Surface Glycoprotein CD28 Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe T Cell Specific Surface Glycoprotein CD28 Revenue (2021-2032)
  11. 7.3.2 Europe T Cell Specific Surface Glycoprotein CD28 Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific T Cell Specific Surface Glycoprotein CD28 Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific T Cell Specific Surface Glycoprotein CD28 Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa T Cell Specific Surface Glycoprotein CD28 Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa T Cell Specific Surface Glycoprotein CD28 Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson T Cell Specific Surface Glycoprotein CD28 Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson T Cell Specific Surface Glycoprotein CD28 Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 TheraMAB LLC
  8. 8.2.1 TheraMAB LLC Company Information
  9. 8.2.2 TheraMAB LLC Business Overview
  10. 8.2.3 TheraMAB LLC T Cell Specific Surface Glycoprotein CD28 Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 TheraMAB LLC T Cell Specific Surface Glycoprotein CD28 Product Portfolio
  12. 8.2.5 TheraMAB LLC Recent Developments
  13. 8.3 Five Prime Therapeutics Inc
  14. 8.3.1 Five Prime Therapeutics Inc Company Information
  15. 8.3.2 Five Prime Therapeutics Inc Business Overview
  16. 8.3.3 Five Prime Therapeutics Inc T Cell Specific Surface Glycoprotein CD28 Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Five Prime Therapeutics Inc T Cell Specific Surface Glycoprotein CD28 Product Portfolio
  18. 8.3.5 Five Prime Therapeutics Inc Recent Developments
  19. 8.4 Bristol-Myers Squibb Co
  20. 8.4.1 Bristol-Myers Squibb Co Company Information
  21. 8.4.2 Bristol-Myers Squibb Co Business Overview
  22. 8.4.3 Bristol-Myers Squibb Co T Cell Specific Surface Glycoprotein CD28 Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb Co T Cell Specific Surface Glycoprotein CD28 Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Co Recent Developments
  25. 8.5 Atox Bio Ltd
  26. 8.5.1 Atox Bio Ltd Company Information
  27. 8.5.2 Atox Bio Ltd Business Overview
  28. 8.5.3 Atox Bio Ltd T Cell Specific Surface Glycoprotein CD28 Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Atox Bio Ltd T Cell Specific Surface Glycoprotein CD28 Product Portfolio
  30. 8.5.5 Atox Bio Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 T Cell Specific Surface Glycoprotein CD28 Value Chain Analysis
  2. 9.1.1 T Cell Specific Surface Glycoprotein CD28 Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 T Cell Specific Surface Glycoprotein CD28 Production Mode & Process
  6. 9.2 T Cell Specific Surface Glycoprotein CD28 Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 T Cell Specific Surface Glycoprotein CD28 Distributors
  9. 9.2.3 T Cell Specific Surface Glycoprotein CD28 Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst